 Amryt Pharma PLC NASDAQ:AMYT LON:AMYT said the US Food and Drug Administration had confirmed its New Drug Application NDA for Oleogel-S10 does not require an Advisory Committee meeting. Oleogel-S10 was developed to treat junctional and dystrophic epidermolysis bullosa EB, where the skin is fragile to even the lightest touch. 